MARKSANS2024-10-012024-12-31 MARKSANS2024-10-012024-12-31 MARKSANS2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member MARKSANS2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member MARKSANS2024-12-31 MARKSANS2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member MARKSANS2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member MARKSANS2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member MARKSANS2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524404 MARKSANS NOTLISTED Marksans Pharma Limited Equity 2024-04-01 2025-03-31 2025-02-11 2025-01-22 INR Millions Third quarter 19:15:00 20:00:00 2025-02-11 2025-02-11 Not applicable Single segment Manufacturing & Marketing of Pharmaceutical Formulations 2024-10-01 2024-12-31 Unaudited Consolidated 6818460000.00 278490000.00 7096950000.00 1892560000.00 1119520000.00 -28660000.00 884420000.00 26670000.00 206880000.00 1562970000.00 5664360000.00 1432590000.00 0.00 1432590000.00 380140000.00 1780000.00 381920000.00 0.00 1050670000.00 0.00 0.00 0.00 0.00 1050670000.00 -380090000.00 670580000.00 1045630000.00 5040000.00 686920000.00 -16340000.00 453164000.00 1 2.31 2.31 0.00 0.00 2.31 2.31 1. The unaudited consolidated financial results for the quarter and nine months ended 31 December 2024 of Marksans Pharma Limited ('the Company' or 'the holding company') and its subsidiaries (collectively referred as 'the Group') were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 11 February 2025. The Statutory Auditors of the Company have carried out limited review on the above results in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation'), as amended and expressed an unmodified conclusion. 2. The unaudited consolidated financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulation. 3. The Group's activities comprise of manufacturing pharmaceutical formulation and trading in pharmaceutical products. The Group has only one reportable segment namely 'Pharmaceuticals' as per Ind AS 108 on 'Operating Segments'. 4. As at 31 December 2024, following are the direct and indirect subsidiaries of the Company: ·         Marksans Pharma (UK) Limited ·         Relonchem Limited ·         Marksans Holdings Limited ·         Bell, Sons and Co. (Druggists) Limited ·         Marksans Pharma Inc. ·         Time-Cap Laboratories Inc. ·         Marise Ann Inc. ·         Custom Coating Inc. ·         Marksans Realty LLC ·         Nova Pharmaceuticals Australasia Pty Ltd ·         Nova Pharmaceuticals Limited ·         Access Healthcare for Medical Products L.L.C ·         Marksans Pharma GmbH 5. The above unaudited consolidated financials results are available on the Company's website (www.marksanspharma.com) and stock exchanges websites, BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 19143870000.00 538570000.00 19682440000.00 5649480000.00 4135130000.00 -1599400000.00 2530820000.00 82250000.00 606410000.00 4399010000.00 15803700000.00 3878740000.00 0.00 3878740000.00 1043130000.00 -83330000.00 959800000.00 0.00 2918940000.00 0.00 0.00 0.00 0.00 2918940000.00 215660000.00 3134600000.00 2900310000.00 18630000.00 3122260000.00 12340000.00 453164000.00 1 6.40 6.40 0.00 0.00 6.40 6.40 Other expenses 1562970000.00 Other expenses 4399010000.00 Remeasurements of the net defined benefit liabilities/assets 950000.00 Remeasurements of the net defined benefit liabilities/assets 2840000.00 950000.00 2840000.00 240000.00 720000.00 Foreign currency translation reserve -380800000.00 Foreign currency translation reserve 213540000.00 -380800000.00 213540000.00 0.00 0.00